HBMHF Stock - HBM Holdings Limited
Unlock GoAI Insights for HBMHF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $38.10M | $89.50M | $40.76M | $4.29M | $14.11M |
| Gross Profit | $33.61M | $87.47M | $32.57M | $-2,629,324 | $8.43M |
| Gross Margin | 88.2% | 97.7% | 79.9% | -61.2% | 59.7% |
| Operating Income | $-2,185,000 | $21.83M | $-122,178,204 | $-142,528,665 | $-81,322,490 |
| Net Income | $2.78M | $22.80M | $-137,548,714 | $-137,323,840 | $-296,478,993 |
| Net Margin | 7.3% | 25.5% | -337.5% | -3198.2% | -2101.1% |
| EPS | $0.00 | $0.03 | $-0.19 | $-0.19 | $-0.39 |
HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; Tanfanercept (HBM9036) to treat moderate to-severe dry eye disease; HBM7008, a bispecific antibody targeting tumor Associated antigen; and HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4. The company is also developing HBM9022 for the treatment of SARS-COV-2; HBM9302 for the treatment of breast and gastric cancers; HBM7020 for the treatment of multiple myeloma; and HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022 for the treatment of solid tumors. It operates in Mainland China, the United States, Europe, and internationally. The company has collaboration on antibody-drug conjugate projects with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. HBM Holdings Limited was incorporated in 2016 and is based in Shanghai, the People's Republic of China.
Visit WebsiteEarnings History & Surprises
HBMHFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 30, 2026 | — | — | — | — |
Q3 2025 | Aug 27, 2025 | — | $0.09 | — | — |
Q1 2025 | Mar 31, 2025 | — | $0.00 | — | — |
Q3 2024 | Aug 28, 2024 | — | $0.00 | — | — |
Q2 2024 | Jun 6, 2024 | — | $0.03 | — | — |
Q2 2023 | Jun 29, 2023 | — | $0.00 | — | — |
Q4 2022 | Dec 30, 2022 | — | $-0.08 | — | — |
Q2 2022 | Jun 29, 2022 | — | $-0.10 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.09 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.09 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.20 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-0.20 | — | — |
Q4 2019 | Dec 31, 2019 | — | $-0.04 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-0.04 | — | — |
Latest News
Frequently Asked Questions about HBMHF
What is HBMHF's current stock price?
What is the analyst price target for HBMHF?
What sector is HBM Holdings Limited in?
What is HBMHF's market cap?
Does HBMHF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to HBMHF for comparison